BriaCell Therapeutics Corp. (TSX:BCT)

Canada · Delayed Price · Currency is CAD

5.57

+0.96 (20.82%)

Nov 6, 2026, 4:00 PM EST

BriaCell Therapeutics Financials Overview

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Jul '26 Jul 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Operating Income	-36.05	-36.05	-27.2	-33.33	-23.27	-15.29
Net Income	-34.9	-34.9	-26.31	-4.79	-20.3	-26.84
Earnings Per Share	-6.97	-6.97	-62.19	-43.68	-194.97	-259.83
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Jul '26 Jul 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Cash & Investments	20.54	20.54	17.87	0.86	21.25	41.04
Total Debt	-	-	-	-	-	-
Net Cash (Debt)	20.54	20.54	17.87	0.86	21.25	41.04
Net Cash Growth	14.97%	14.97%	1972.44%	-95.94%	-48.22%	-28.30%
Net Cash Per Share	4.10	4.10	42.23	7.86	204.08	397.33

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Jul '26 Jul 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Operating Cash Flow	-28.65	-28.65	-28.17	-24.13	-23.74	-12.48
Capital Expenditures	-0.13	-0.13	-	-0.46	-	-
Free Cash Flow	-28.78	-28.78	-28.17	-24.58	-23.74	-12.48
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.